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Background: Allergic respiratory diseases are constantly increasing in prevalence. Allergen Immunotherapy (AIT)
represent a valuable therapeutic tool as symptomatic and preventative approach, expecially in children. In Italy,
primary care pediatricians (PCP) represent the first-line contact and interface for prescription, use and management
of AIT. We attempted to evaluate the perception of AIT practice among PCP.
Methods: A questionnaire was built-up, based on literature, guidelines and with the contribution of pediatricians.
The questionnaire, including 12 items, was e-mailed to 180 PCP, randomly chosen from mailing lists. The questionnaire
explored the personal perception of AIT, the comparison between subcutaneous and sublingual AIT and the overall
awareness about the treatment.
Results: 130 questionnaires were eligible for analysis. There was a satisfactory knowledge of the characteristics of AIT,
its aims and limits, although the positioning of the treatment in guidelines was insufficiently known. Overall, the
prescription of AIT made by other specialists was accepted and agreed (78 %). The majority of pediatricians felt that a
more intense divulgation and information about AIT would be needed (90 %).
Conclusion: AIT is in general well known and accepted among PCP, although a more intense divulgation effort is required.
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The prevalence of allergic respiratory diseases (rhinitis and
asthma) constantly increased in the second half of the last
century. Nowadays, although the prevalence of asthma
seemed to plateau, that of rhinitis is still increasing. This fact
may be attributable to different factors, including the
“westernization” of lifestyle, the reduction of infectious dis-
eases, and the increased allergenic burden linked to climate
changes [1, 2]. Concerning Italy, the SIDRIA survey [3], con-
ducted in 1994–95 and 2002, confirmed the plateau of
asthma prevalence (about 10 % in both children and adoles-
cents), and the significant increase of rhinitis (from 6 to 9 %
in children and from 14 to 17 % in adolescents). In this* Correspondence: passalacqua@unige.it
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creativecommons.org/publicdomain/zero/1.0/survey, no relevant difference could be seen in the geo-
graphical distribution of respiratory allergies, with a slightly
higher occurrence of the symptom cough in large urban ag-
glomerates with respect to rural areas.
In the pediatric age range, allergic diseases represent a
special problem, with specific aspects, that include their
possible evolution (allergic march) [4–6], the problems
related to the long-term pharmacotherapy, the compli-
ance (which is in charge of caregivers), the objective dif-
ficulties in correctly deliver inhaled drugs. In addition,
the quality of life of the children themselves and of their
parents (drug treatment, emergency unit visits, impaired
school performance and absenteeism), is usually affected
[7, 8]. Thus, an early and correct diagnosis and an ad-
equate therapeutic management of allergic respiratory
diseases in children are strongly desirable [9].
Many clinical trials and meta-analyses have convincingly
demonstrated that allergen immunotherapy (AIT) isicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 The questionnaire and percentage of responses
N Item Percent
1 AITs is :
a. a treatment to contrast the allergen-related symptoms
in general
32.7
b. a target organ treatment (rhinitis/asthma) 10
c. an alternative to pharmacotherapy 1.6
d. a complementary adjunct when pharmacotherapy is not
sufficient to control symptoms
55.7
2 Do you consider AIT useful/effective in allergic rhinitis?
a. Yes, always. 8.6
b. Yes, in most cases 44.5
c. Only in selected cases 34.4
d. No 12.5
3 Do you consider AIT useful/effective in allergic bronchial asthma?
a. Yes, always. 17.3
b. Yes, in most cases 49.6
c. Only in selected cases 31.5
d. No 1.6
4 According to your clinical practice, does AIT result in a pharmaco-
economic saving?
a. Yes, always. 37.5
b. Only in selected cases 49.2
c. No 4.7
d. No opinion 8.6
5 Do you think that AIT adds clinical beneficial effects to standard
treatment?
a. Yes, always. 47.6
b. Only in selected cases 43.7
c. No 6.3
d. No opinion 2.4
6 Based on your experience/literature, do you think that AIT can
prevent the onset of new sensitizations?
a. Yes, always. 24.2
b. Only in selected cases 33.6
c. No 26.6
d. No opinion 15.6
7 Based on your experience/literature, do you think that AIT can
modify the progression of disease?
a. Yes, always. 30.7
b. Only in selected cases 59.8
c. No 9.5
d. No opinion 0
8 Based on your experience and literature, do you think that SCIT and
SLIT are equivalent for safety?
a. Yes 22.8
b. NO, SCIT is better than SLIT 12.6
c. NO, SLIT is better than SCIT 56.7
d. No opinion 7.9
Table 1 The questionnaire and percentage of responses
(Continued)
9 When a children is prescribed with AIT by the specialist, which is
your attitude?
a. Agree at all 78.4
b. I require more details 18.4
c. Disagree 1.6
d. Indifferent 1.6
10 Based on your experience and literature, do you think that SCIT and
SLIT are equally effective?
a. Yes 45.3
b. No, SCIT is better than SLIT 23.4
c. No, SLIT is better than SCIT 10.2
d. Do not know 21.1
11 Do you think that more interest should be deserved to AIT in the
congresses you usually attend?
a. Yes 92.9
b. No 7.1
12 In international guidelines for rhinitis (ARIA) and asthma (GINA) is
AIT mentioned?
a. Yes, in both 55.4
b. No 24.8
c. Only in ARIA guidelines 8.3
d. Only in GINA guidelines 11.6
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with a consequent improvement of the overall quality of
life. More importantly, there is evidence that AIT can mod-
ify the natural history of allergic disease, for instance
preventing the onset of asthma in patients with allergic
rhinitis and/or maintaining a long-lasting effect [10]. The
introduction of the sublingual route of administration
(SLIT) in clinical practice represented an important step
forward, of particular relevance in the pediatric age [11].
In this case, the good safety profile (very low risk of severe
adverse events), the convenience and the management at
home, allowed to expand the indications. In fact, more
and more often SLIT is prescribed to children below the
age of 5 years [12, 13].
Pediatricians are the first-line specialists who afford the
problems related to respiratory allergy, to the prescription
and to management of AIT. In Italy, the figure of the
“primary care” pediatrician, makes the situation even more
peculiar, since those healthcare specialists remain a solid
and constant contact with children and families. Based
on these premises we performed a questionnaire-based sur-
vey among Italian primary care pediatricians to assess their
knowledge and information about the use of AIT.
Methods
A 12-item questionnaire was built up, based on the
current literature, Position Papers [14–16], expert
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care pediatricians (Table 1). The questionnaire, involv-
ing prescription attitudes, follow-up of patients, aware-
ness about the treatment, had multiple choice options.
The questionnaire was e-mailed to primary care pedia-
tricians, randomly chosen from the mailing lists of par-
ticipants to meetings over the whole Italian territory.
The study was observational and cross sectional, there-
fore only required notification to the local Ethic
Committees, according to the Italian laws. The partici-
pating pediatricians were required to refer only to those
patients for whom the diagnosis of respiratory allergy,
and the prescription of AIT were clearly established,
possibly made by pediatric allergists/pulmonologists.
Results
The questionnaire was e-mailed to 180 primary care
pediatricians, of whom 140 responded. Out of the 140
returned questionnaires, 130 were eligible for analysis
since correctly and completely filled. The respondentTable 2 Percentage of positive responses to each item according to
Itema North Center South
(N = 38) (N = 33) (N = 59)
% % %
1 a 37 38 28
1 b 11 7 10
1 c 0 0 5
1 d 52 55 57
2 a 7 9 9
2 b 39 44 54
2 c 41 36 28
2 d 13 11 9
23 a 14 23 18
3 b 55 32 55
3 c 31 45 23
3 d 0 0 4
4 a 43 41 30
4 b 45 45 56
4 c 4 7 4
4 d 8 7 10
5 a 53 61 46
5 b 39 30 48
5 c 5 9 6
5 d 3 0 0
6 a 24 31 22
6 b 38 38 36
6 c 21 24 24
6 d 17 7 12
No significant difference among the 3 regions was detectable for all items
aFor the description of each item refer to Table 1pediatrician had an age of 55 ± 8.3 years, and 50 of them
were male. All of them were obviously employed in the
primary care service. On average, each pediatrician was in
charge of about 1,000 children (1050 ± 245). The pediatri-
cians resulted to be distributed as follows: northern (31 %)
central (24 %) and southern (46 %) Italy, with
no difference in gender and age distribution among the
three geographical regions. The results are reported in
Table 1. As per responses, there was a satisfactory know-
ledge of the characteristics of AIT, its aims and limits.
Overall, the prescription of AIT made by other specialists
(pediatric allergist/pulmonologist) was accepted and
agreed (78 %). Of note, the majority of pediatricians felt
that a more intense divulgation and information about
AIT would be needed (90 %). There was no difference
in the distribution of the answers according to gender (not
shown), and a comparative analysis according to age range
could not be made due to the important skew
towards older ages (80 % of respondents over 45 years
of age and 94 % over 35 years). Also, no geographical-the geographical location
Itema North Center South
(N = 38) (N = 33) (N = 59)
% % %
7 a 30 28 31
7 b 60 64 56
7 c 10 7 13
7 d 0 0 0
8 a 18 21 24
8 b 11 20 12
8 c 60 59 54
8 d 11 10 10
9 a 76 78 78
9 b 20 19 16
9 c 2 0 4
9 d 2 3 2
10 a 48 51 42
10 b 16 24 27
10 c 16 6 8
10 d 20 22 23
11 a 93 96 95
11 b 7 4 5
12 a 45 45 41
12 b 23 18 26
12 c 12 18 20
12 d 20 19 13
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the area of residency, as summarized in Table 2.Discussion
As mentioned above, AIT is the only allergen-oriented
therapy, and acts as a disease-modifying treatment.
Thus, AIT can not only modify symptoms in the short-
medium term period, but can change the progression of
the disorder. The disease-modifying effect can be seen as
the reduction of the risk of asthma onset in children
with rhinitis, and as the persistence of the clinical bene-
fit for several years after the discontinuation [10, 17–19].
These facts assume a special relevance in the pediatric
age, when the plasticity and modulability of the immune
system are maximal, and when the preventative effects
can be reasonably expected.
In Italy, children are followed-up by the institutional
primary care pediatrician, an almost unique figure all
over the world (the equivalent of the general practitioner
for adults), who faces daily allergic diseases and their
management as first-line referral. AIT is usually pre-
scribed by pediatric allergists (a subspecialty in Italy),
who diagnose the disease and chose the most appropri-
ate AIT, then leaving it in the hands of the primary care
pediatricians. In such a setting, we considered of primary
importance to know which is the perception of and the
attitude toward AIT within general pediatricians. This
was explored by a simple questionnaire developed by
a panel of experts, on the basis of the literature, and
agreed with a representative number of primary care col-
leagues. According to the results, the overall knowledge
on the specific argument seems to be satisfactory. Not-
ably, about 50 % of pediatricians still believe that AIT
is an add-on therapy to be used when pharmacotherapy
fails. Another important aspect is that only one half
of the interviewed pediatricians are aware of the fact
that AIT is mentioned in the major guidelines. Finally,
and probably according to the mentioned responses, the
majority of primary care pediatrician agree on the fact
that a more intense divulgation effort on the specific ar-
gument is worthwhile. The main limitation of this study
stands in the questionnaire-based method, with the
questionnaire prepared by a restricted group of experts.
Nonetheless, it has to be considered that, to obtain a sat-
isfactory response, the questionnaire itself had to be kept
as simple and as short as possible. In addition, since no
explanation or information on AIT was provided when
the questionnaires were mailed, we can assume that the
responses truly reflect the reality. Finally it is not pos-
sible to compare our results with other similar, since the
primary care pediatircian is a professional figure that is
present only in our Country (and very few others), and
no survey in this sense has been attempted in the past.Conclusion
As a general consideration, the results herein reported
are overall in agreement with those described for Italian
general practitioners and chest physicians, who were
previously interviewed using similar questionnaires [20, 21].
This facts indirectly testifies that there is an increasing
awareness about AIT among physicians, as repeatedly aus-
picated [22].
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